{"entity":{"id":"nct07219576","kind":"trial","name":"Retifanlimab and Ruxolitinib In Solid Malignancies","aka":["PRISM"],"tldr":"A phase 1/2 trial of ruxolitinib and retifanlimab in lung cancer, run by University of California, San Diego, now recruiting.","summary":"Retifanlimab and Ruxolitinib In Solid Malignancies is a phase 1/2, interventional study registered as NCT07219576 by University of California, San Diego, with a registry enrolment figure of 40 participants, started 2026-01-08 and due to reach its primary completion in 2027-12. Interventions recorded: Ruxolitinib; Retifanlimab. Conditions listed: Non Small Cell Lung Carcinoma; Renal Cell Carcinoma. Primary outcome: Recommended phase 2 dose. Lung eligibility wording from the registry: \"Advanced or metastatic clear cell renal cell carcinoma or non-small cell lung carcinoma having progressed on prior PD-1/PD-L1 therapy (radiographic progression within 6 months of discontinuing immunotherapy; immunotherapy does not need to be the immediate line of preceding therapy)\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07219576","url":"https://clinicaltrials.gov/study/NCT07219576"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["ruxolitinib","retifanlimab"],"companies":["incyte"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07219576","phase":"1/2","setting":"PRISM: Phase 1b of Retifanlimab and Ruxolitinib In Solid Malignancies Progressing on Prior Checkpoint Inhibition","sponsor":"University of California, San Diego","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07219576/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"retifanlimab","kind":"drug","name":"Retifanlimab","route":"/drugs/retifanlimab/"},{"id":"ruxolitinib","kind":"drug","name":"Ruxolitinib","route":"/drugs/ruxolitinib/"}],"company":[{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}